More importantly, we have demonstrated that the inhibition of ADAM17 proteolytic activity with a neutralizing antibody could prevent IFN-γ degradation, strongly suggesting that such inhibition could be utilized as a therapeutic approach to enforce cancer immune surveillance and inhibit osteoclastic bone resorption during bone cancer metastasis. This evidence concerns the gene ADAM17 and bone cancer.